Stan Wang, MD, PhD, is CEO & Founder of Thymmune Therapeutics, a biotechnology company developing a machine learning-enabled thymic cell engineering platform to restore normal immune function in aging and disease. The company's cutting-edge approach in iPSC-thymic cell manufacturing can generate off-the-shelf cells at scale for a pipeline of therapies to treat immunodeficiencies, transplant related, and autoimmune disorders. Previously, he was Founding Chief Scientific Officer at Cellino Biotech.

Dr. Wang received his PhD in stem cell biology & regenerative medicine from the University of Cambridge as a Gates Scholar and NIH-Cambridge Scholar, and his MD from Columbia University via the NIH Medical Scientist Training Program. He was a postdoctoral fellow with George Church at Harvard Medical School.